Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins
Anthem Biosciences Ltd · Investor Presentation · 03 Nov 2026, 11:43 pm
Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins Anthem Biosciences reported Q2FY27 consolidated revenue from operations of ₹5,940 Mn, up 7.9% YoY and 42.0% QoQ, driven by CRDMO sales of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins expanding 610 bps YoY to 50.6%. PAT increased 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1FY27, revenue reached ₹10,123 Mn, EBITDA stood at ₹5,059 Mn (46.2% margin), and PAT was ₹3,314 Mn. As of 30th Sep'26, net cash totaled ₹15,380 Mn.
Original exchange filing (PDF)
More announcements from Anthem Biosciences Ltd
- Transcript of Q2 & H1 FY27 Earnings Conference Call · 06 Nov 2026
- Audio recording of Earnings Call for the quarter ended September 30, 2026. · 05 Nov 2026
- Intimation of Schedule of Analyst Meet/Institutional Meet · 05 Nov 2026
- Press release for the financial results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Submission of the outcome of the Board Meeting held on November 03, 2026, for approval of the Unaudited Financial results for the quarter and half year ended September 30, 2026. · 03 Nov 2026
- Submission of outcome of the Board Meeting approving the Unaudited Financial results for the quarter and half year ended September 30, 2026, on November 03, 2026 · 03 Nov 2026
- Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026. · 03 Nov 2026
- Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 04 Nov 2026
